Intellia Therapeutics (NTLA) Share-based Compensation (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Share-based Compensation of $10.5 million for Q1 2026, down 51.92% year-over-year from $21.8 million in Q1 2025, and down 37.27% quarter-over-quarter from $16.7 million in Q4 2025.
Intellia Therapeutics (NTLA) Share-based Compensation (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Share-based Compensation for 12 consecutive years, with $10.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 51.92% year-over-year to $10.5 million; the TTM figure through Mar 2026 stood at $10.5 million (down 89.55% YoY), while the FY2025 annual figure was $80.2 million, down 28.9% from the prior year.
- Share-based Compensation declined to $10.5 million in Q1 2026 per NTLA's latest filing, from $16.7 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $40.9 million in Q2 2024 and bottomed at -$1.8 million in Q4 2024.
- Historically, Share-based Compensation has averaged $23.1 million across 5 years, with a median of $23.1 million in 2022.
- Annual changes were most pronounced in 2023 — Share-based Compensation jumped 12460.22% — and 2024, when it plunged 105.24%.
- Intellia Therapeutics' Share-based Compensation stood at $279000.0 in 2022, then surged by 12460.22% to $35.0 million in 2023, then slumped by 105.24% to -$1.8 million in 2024, then soared by 1012.21% to $16.7 million in 2025, then plunged by 37.27% to $10.5 million in 2026.
- Business Quant data shows NTLA's Share-based Compensation at $10.5 million in Q1 2026, $16.7 million in Q4 2025, and $7.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | 18.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.08 Mn |
| Jun 30, 2026 | 18.08 Mn |
| Mar 31, 2026 | 10.50 Mn |
| Mar 31, 2026 | 10.50 Mn |
| Dec 31, 2025 | 16.74 Mn |
| Dec 31, 2025 | 16.74 Mn |
| Sep 30, 2025 | 7.90 Mn |
| Sep 30, 2025 | 7.90 Mn |
| Jun 30, 2025 | 22.04 Mn |
| Jun 30, 2025 | 22.04 Mn |
| Mar 31, 2025 | 21.84 Mn |
| Mar 31, 2025 | 21.84 Mn |
| Dec 31, 2024 | -1.84 Mn |
| Dec 31, 2024 | -1.84 Mn |
| Sep 30, 2024 | 39.62 Mn |
| Sep 30, 2024 | 39.62 Mn |
| Jun 30, 2024 | 40.86 Mn |
| Jun 30, 2024 | 40.86 Mn |
| Mar 31, 2024 | 34.18 Mn |
| Mar 31, 2024 | 34.18 Mn |